NOTA! Questo sito utilizza i cookie e tecnologie simili.

Se non si modificano le impostazioni del browser, l'utente accetta. Per saperne di piu'

Approvo

13th Meet The Professor

Advanced International Breast Cancer Course (AIBCC)

Padua, September 21st - 23rd 2017



  • Aims
  • Awards & Fellowships
  • Directors
  • Scientific Committee
  • Speakers & Chairmen
  • Program
  • Registration

Breast cancer represents the front runner in cancer research in many aspects. First, this is a common, chronic and lethal disease where medical interventions are successfully inducing a continuous decline in mortality in spite of increasing incidence. Second, biology drives the entire diagnostic-therapeutic work up of these patients. This is why, nowadays, a breast multidisciplinary team should also include pathologists, molecular biologists, oncogeneticists besides the “classic” clinical specialties. Third, many highly effective interventions are available for each step of the diagnostic and therapeutic work-up of these patients. The increased complexity of the disease, the availability of multiple effective choices and the high expectations of our patients are raising the bar of clinical excellence in this field.
With this goal in mind, the Programme of this international Conference includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes.
Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.
This 13th Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where international opinion leaders and attendees will exchange experiences and share the most exiting advances.
In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 13th AIBCC will award the 7th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year.
We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere.

Addressed to

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists and nurses.

Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

CME

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will request the MCE Accreditation.

The Meeting is addressed to physicians specialized in oncology, radiodiagnostics, radiotherapy, clinical pathology, general surgery, gynaecology and obstetrics, biologists and nurses. It will not be possible to give credits to physicians specialized in different fields.

The credit certification is subject to:

  • attendance at the 90% of the Meeting
  • the completion of the Meeting evaluation form
  • the completion of the final questionnaire (at least 75% of correct answers)

We would like to remind you to participants that only 1/3 of CME credits acquired during the years 2017/2019 can come from a sponsorship.

 

UNIVERSITY OF PADUA AWARD FOR ADVANCES IN BREAST CANCER 2017

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. The winner will be invited to present his/her study during the annual Conference.

CASE HISTORIES

Participants can send one or more case history to the scientific committee. The selected ones will be discussed during one of the three tumor boards (please see the program). People sending the selected case histories will have to present them and will have free registration, dinners and accommodation as well as a reimbursement of travel expenses (max of travel reimbursement 200,00 € for Italian participants and €300,00 for European participants). Case histories should be sent within July 1st. A confirmation will be sent by email within July 20th. For further details (such as time limit, number of slides to prepare and so on) please do not hesitate to send an email to Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.

FELLOWSHIPS

Some fellowship (for under 40) will be awarded which will include registration and 3 Hotel nights. Those interested should send the registration form together with a short CV and a motivation letter within July 1st. The organizing secretariat will confirm the award of the fellowship within July 20th and it will proceed with the organization of logistics.

UNDER 35

Free admission is available for 3 people "under 35". Registration forms will be accepted on a first-come, first-served basis until spaces will be full. The Organization Secretariat will confirm the registration by email.

Foto

Pier Franco Conte

Division of Medical Oncology 2

Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padua (I)

Foto

Gabriel N. Hortobagyi

Department of Breast Medical Oncology

The University of Texas - MD Anderson Cancer Center
Houston (USA)

Hesham Ahmed Gaballah Elghazaly

Department of Clinical Oncology and nuclear medicine
University of Ainshams
Cairo (EG)

Valentina Guarneri

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Jacek Jassem

Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)

Stephen Johnston

NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)

Sibylle Loibl

German Breast Group
Department of Medicine and Research
University of Frankfurt (D)

Miguel Martin

Medical Oncology Service
Hospital Universitario Gregorio Marañon
Madrid (S)

Stefania Migliuolo

Europa Donna Italia
Milan (I)

Fedro Alessandro Peccatori

Department of Medical Oncology
European Institute of Oncology (IEO)
Milan (I)

Philip Poortmans

President-elect of ESTRO
Department of Radiation Oncology
Radbound University Medical Centre
Nijmegen (NL)

Aleix Prat

Institute of Oncology (VHIO)
Vall d’Hebron- Institute of Oncology
Barcellona (E)

[Preliminary Faculty]

Enrica Baldan

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Francesco Bertolini
Department of Emato-Oncology
European Institute of Oncology
University of Milan (I)
Fernando Bozza

Division of Breast Surgery
Istituto Oncologico Veneto IRCCS
Padua (I)

Maria Joao Cardoso

Breast Unit
Fondation Champalimaud
Lisbon (P)

Javier Cortes Castan

Institute of Oncology
Vall d’Hebron (VHIO)
Barcellona (S)

Giuseppe Curigliano

Department of Oncology
European Institute of Oncology
University of Milan (I)

Andrea De Censi

Medica and Preventive Oncology
E.O. Galliera Hospital
Genua (I)

Leticia De Mattos-Arruda

Institute of Oncology
Vall d’Hebron (VHIO)
Barcellona (S)

Maria Vittoria Dieci

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Peter Dubsky

Surgery Unit
University
Wien (A)

Marco Gambacciani

Obstetrics & Gynecology Unit
S. Chiara Hospital
Pisa (I)

Oreste Gentilini

Breast Unit
S. Raffaele Hospital
Milan (I)

Eleuterios Mamounas

Comprehensive Breast Program
MD Anderson Cancer Center
Orlando (USA)

Marco Montagna

Hereditary Tumors Group Breast and Ovary Cancer
Department of Oncological Molecular Diagnostic and Immunology
Istituto Oncologico Veneto
University of Padua (I)

Stefania Montemezzi

Department of Radiology
University Hospital
Verona (I)

Enrico Orvieto

General Pathology and Cythopatology Unit
Department of Medicine-DIMED
University of Padua (I)

Luigi Pescarini

Department of Radiology
Diagnostic Breast Unit
Istituto Oncologico Veneto IRCCS
University of Padua (I)

Massimo Rugge

General Pathology & Cytopathology Unit
Department of Medicine-DIMED
University of Padua (I)

Hope Rugo

Breast Oncology Clinical Trials Program
UCSF Carol Franc Buck Breast Care Center
San Francisco (USA)

Peter Schmid

Centre for Experimental Cancer Medicine
Bart Cancer Institute
Queen Mary University
London (UK)

Giuseppe Viale

Department of Pathology
European Institute of Oncology
University of Milan (I)

Vincenzo Vindigni

Unit of Plastic and Reconstructive Surgery
University of Padua (I)

Preliminary Program

Thursday, September 21st

8.00

Registration

9.15

Introduction to the Conference
Pier Franco Conte, Gabriel N. Hortobagyi

SESSION I - LIFE STYLE AND BREAST CANCER

 

9.30

Body Mass Index: role as risk factor and predictor of endocrine therapy efficacy

10.00

Hormone replacement therapy: the good and the bad

10.30

Breast cancer and pregnancy

11.00

Q&A

11.30

Coffee break

SESSION II - HIGH RISK WOMEN AND PERSONALISED SCREENING

 

11.45

Identification of high risk women: from family history to multigene panels

12.15

Personalized screening (including women with dense breasts or breast implants/augmentation)

12.45

Q&A

13.10

Lunch

14.00

Multidisciplinary Tumor Board 1 – Management of women at high risk of breast cancer
Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncogenetists, radiologists, surgeons, oncologists and representatives of advocacy group will comment the votes and express their opinions.

SESSION III - SURGERY & RADIOTHERAPY

 

15.00

Management of in situ carcinoma: state of art

15.30

Sentinel node biopsy: when should be spared?

15.50

Sentinel node biopsy: before or after NACT?

16.10

Lipofilling: are preclinical data fully reassuring?

16.30

Lipofilling after breast cancer: the surgeon’s point of view

16.50

Radiation therapy: when more is better and when less is good

17.20

Q&A

17.30

Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2017

18.00

Lecture of the Awardee

18.30

Cocktail

20.00

Adjourn

Friday, September 22nd

SESSION IV - PATHOLOGY, GENOMICS & MOLECULAR BIOLOGY

 

9.00

Baseline assessment: new AJCC classification

9.30

HER2 testing guidelines for the clinicians: equivocal means yes or no?

10.00

Genomic tests: clinical utility after TailoRx and Mindact

10.30

Liquid biopsy (ctDNA, CTC, miRNA): ready for clinical use?

11.00

Q&A

11.15

Coffee break

11.30

SESSION V – ACTIONABLE PATHWAYS IN BREAST CANCER SUBTYPES

 

11.45

Luminal tumors and endocrine resistance

12.15

Targeting the immune system: TN and beyond

12.45

HER2+ and trastuzumab resistance

13.15

Q&A

13.30

Lunch

14.30

Multidisciplinary Tumor Board 2 – Challenging cases for pathologists and clinicians (including CUP syndrome, breast cancer during pregnancy)
Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncogenetists, radiologists, surgeons, oncologists and representatives of advocacy group will comment the votes and express their opinions.

16.00

Coffee break

SESSION VI – ADJUVANT TREATMENTS

 

16.20

HR+ disease: when more is better, when less is good

17.00

HER2+ disease: when more is better, when less is good

17.40

Triple Negative: when more is better, when less is good

18.20

Q&A

18.30

Adjourn

Saturday, September 23rd

SESSION VIII – ABC PATIENTS

 

9.00

New therapeutic algorithms
HR+ ABC
HER2+ ABC
TN ABC

10.30

Q&A

10.45

Highlights from major meeting (ASCO, ESMO, SABCS, ST GALLEN)

11.15

Coffee break

11.45

Multidisciplinary Tumor Board 3 – Management of advanced breast cancer
Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncologists, pathologists, radiologists, radiation oncologists, surgeons and representatives of advocacy group will comment the votes and express their opinions.

13.15

Adjourn and final evaluation questionnaire

Registration Fee

€ 250.00

Tax free.

It includes the conference bag, the conference book and all coffee breaks and lunches. It does not include Hotel accomodation, dinners and travel expenses.


Under 35

Free admission is available for 3 persons “under 35”. Registration forms will be accepted on a first-come, first-served basis unitil spaces are filled. The Organization Secretariat will confirm the registration by email.

Click on the following button to open the on line registration form (in italian language):

Enroll

Meeting Venue

Palazzo del Bo, Via VIII Febbraio 2, Padova.
+39.049.803.37.11

 

How to reach the meeting venue